Mild Cognitive Impairment – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Mild Cognitive Impairment – Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
- The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects
- The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Actinogen Medical LtdAcumen Pharmaceuticals Inc
Addex Therapeutics Ltd
AgeneBio Inc
Amylyx Pharmaceuticals Inc
ANLBio Co Ltd
Araclon Biotech SL
AriBio Co Ltd
Biomed Industries Inc
BioVie Inc
CereSpir Inc
Chang Gung Memorial Foundation
Cognigenics Inc
CuraSen Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Filament Health Corp
FUJIFILM Toyama Chemical Co Ltd
Gray Matter
Grespo AB
ImmunoChem Therapeutics LLC
Innovation Pathways LLC
IntelGenx Corp
Jupiter Neurosciences Inc
KeifeRx LLC
Merck & Co Inc
NeurAegis Inc
Neuraly Inc
NKGen Biotech Inc
Novartis AG
Novo Nordisk AS
Oligomerix inc
Pfizer Inc
ProNeurogen Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
SciSparc Ltd
Shackelford Pharma Inc
SinoMab Bioscience Ltd
TauRx Therapeutics Ltd
Thomas Jefferson University
UCB SA
University of California
Vandria SA
Vivoryon Therapeutics NV